相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test
Debbie M. Jakubowski et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Hiroji Iwata et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Oncotype DXA® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy
Alison M. Pease et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
Akiko Chiba et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Harry D. Bear et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
P. A. van Dam et al.
EJSO (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas
Geza Acs et al.
MODERN PATHOLOGY (2012)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.
J. Anderson et al.
CANCER RESEARCH (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
Jenny C. Chang et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
